

Press Release

Singapore 22 June 2018

Study with IQWave™ D-EECT gets Ethical Committee approval

Today Friday 22nd of June 2018 ChemoTech's IQWave™ D-EECT (Dynamic-ElectroEnhanced Chemotherapy™) treatment received approval from the Ethical Committee at Pusat Perubatan Universiti Malaya ('PPUM') in Kuala Lumpur, Malaysia.

We are very proud to announce that the Ethical Committee at PPUM has approved the suggested study on IQWave™ D-EECT for larger locally advanced tumours. The study may start as soon as Abex Medical System Sdn. Bhd. ('ABEX') receives its first IQWave™-device and the treating doctors have been trained and certified from one of ChemoTechs global Key Opinion Leaders.

The study will initially include a small number of patients under the 'special access program' that PPUM received approval for earlier this year.

Once again ABEX has through its professionalism showed us that they value our partnership deeply and has allocated all the resources needed to launch IQWave™ in Malaysia, says Mohan Frick, CEO at ChemoTech.

PPUM is formerly known as 'University Hospital' is a government-funded medical institution located in Pantai Dalam, southwest corner of Kuala Lumpur, the dynamic and bustling capital city of Malaysia. It was established by Statute in September 1962 and is part of University of Malaya. The objectives of PPUM are to establish, operate and develop a medical centre of international standard and repute; and to co-operate with Faculty in providing facilities for medical education, training, research, internship and consultancy.

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by the agency of below stated contact person, to be made public on Friday June 22nd 2018 at 10.30 (CET).

For more information, please contact:

Mohan Frick, CEO
+46 (0)10-218 93 00
+65 9014 5008
info@chemotech.se

Scandinavian ChemoTech AB (publ)

www.chemotech.se

ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.